Overview

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.

Phase:

Phase 2

Details

Lead Sponsor:

Arete Therapeutics

Treatments:

1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-urea